177 related articles for article (PubMed ID: 35773608)
1. EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation.
Fu C; Wang J; Pallikkuth S; Ding Y; Chen J; Wren JD; Yang Y; Wong KK; Kameyama H; Jayaraman M; Munshi A; Tanaka T; Lidke KA; Zhang XA
Cell Mol Life Sci; 2022 Jun; 79(7):389. PubMed ID: 35773608
[TBL] [Abstract][Full Text] [Related]
2. EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer.
Wang J; Wren JD; Ding Y; Chen J; Mittal N; Xu C; Li X; Zeng C; Wang M; Shi J; Zhang YH; Han SJ; Zhang XA
Cancer Lett; 2022 Jun; 536():215641. PubMed ID: 35339615
[TBL] [Abstract][Full Text] [Related]
3. EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy.
Ding Y; Chen J; Li S; Wren JD; Bajpai AK; Wang J; Tanaka T; Rice HC; Hays FA; Lu L; Zhang XA
Oncogene; 2023 Mar; 42(12):861-868. PubMed ID: 36788350
[TBL] [Abstract][Full Text] [Related]
4. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells.
Zhang XA; Lane WS; Charrin S; Rubinstein E; Liu L
Cancer Res; 2003 May; 63(10):2665-74. PubMed ID: 12750295
[TBL] [Abstract][Full Text] [Related]
5. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.
Buonato JM; Lazzara MJ
Cancer Res; 2014 Jan; 74(1):309-19. PubMed ID: 24108744
[TBL] [Abstract][Full Text] [Related]
6. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
Li L; Zhang S; Li H; Chou H
BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway.
Sheng W; Chen C; Dong M; Wang G; Zhou J; Song H; Li Y; Zhang J; Ding S
Cell Death Dis; 2017 Oct; 8(10):e3147. PubMed ID: 29072694
[TBL] [Abstract][Full Text] [Related]
8. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.
Walsh AM; Lazzara MJ
J Cell Sci; 2013 Oct; 126(Pt 19):4339-48. PubMed ID: 23868981
[TBL] [Abstract][Full Text] [Related]
9. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
Walsh AM; Lazzara MJ
Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
[TBL] [Abstract][Full Text] [Related]
10. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
11. TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity.
Lee Y; Ko D; Yoon J; Lee Y; Kim S
J Exp Clin Cancer Res; 2021 Mar; 40(1):58. PubMed ID: 33641663
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
13. Phoyunnanin E inhibits migration of non-small cell lung cancer cells via suppression of epithelial-to-mesenchymal transition and integrin αv and integrin β3.
Petpiroon N; Sritularak B; Chanvorachote P
BMC Complement Altern Med; 2017 Dec; 17(1):553. PubMed ID: 29284478
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
15. RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway.
Li M; Cai L; Wang X; Yu Y; Jian W; Bao G; Gao Z; Guo J; Zhang J; Li C; Zhang C
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34581421
[TBL] [Abstract][Full Text] [Related]
16. EGFR is a pivotal player of the E2/ERβ - mediated functional properties, aggressiveness, and stemness in triple-negative breast cancer cells.
Kyriakopoulou K; Kefali E; Piperigkou Z; Riethmüller C; Greve B; Franchi M; Götte M; Karamanos NK
FEBS J; 2022 Mar; 289(6):1552-1574. PubMed ID: 34665934
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.
Zhou X; Hu Y; Dai L; Wang Y; Zhou J; Wang W; Di W; Qiu L
PLoS One; 2014; 9(5):e96718. PubMed ID: 24816687
[TBL] [Abstract][Full Text] [Related]
18. Dual clathrin and integrin signaling systems regulate growth factor receptor activation.
Alfonzo-Méndez MA; Sochacki KA; Strub MP; Taraska JW
Nat Commun; 2022 Feb; 13(1):905. PubMed ID: 35173166
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors.
Javadi S; Zhiani M; Mousavi MA; Fathi M
Eur J Cell Biol; 2020 May; 99(4):151083. PubMed ID: 32381360
[TBL] [Abstract][Full Text] [Related]
20. TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma.
Pallier K; Cessot A; Côté JF; Just PA; Cazes A; Fabre E; Danel C; Riquet M; Devouassoux-Shisheboran M; Ansieau S; Puisieux A; Laurent-Puig P; Blons H
PLoS One; 2012; 7(1):e29954. PubMed ID: 22272264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
